Acute Treatment of Vestibular Migraine by Rimegepant

NCT ID
NCT07871097
Registry status
Recruiting
Study type
Interventional
Phase
Phase 4
Sponsor
Wensheng Qu
Conditions
Vestibular Migraine

Overview

ClinicalTrials.gov lists this study as Recruiting.

Official title: Efficacy of Rimegepant in the Treatment of Acute Vestibular Migraine -- Multicenter, Prospective, Cross-design, Randomized, Placebo-controlled Study

Enrollment: 80 participants (Estimated).

What is being studied

  • Drug: First dose placebo, second dose rimegepant
  • Drug: First dose rimegepant, second dose placebo

Who may be eligible

Ages
18 Years to 60 Years
Sex
All
Healthy volunteers accepted
No

ClinicalTrials.gov lists the following eligibility criteria.

Inclusion Criteria: 1. Age 18-60 years, male or female. 2. Diagnosis of vestibular migraine according to the Bárány Society criteria. 3. ≥4 episodes of characteristic vestibular symptoms in the past year, each of moderate to severe intensity and lasting \>2 hours (without intervention). 4. Signed informed consent obtained from the participant. Exclusion Criteria: 1. Presence of other disorders causing acute vestibular symptoms (e.g., Ménière's disease, otitis media). 2. Coexisting non-vertiginous dizziness (e.g., dizziness due to panic disorder), unless the patient can clearly distinguish these episodes from vestibular-migraine attacks. 3. Severe hepatic dysfunction (ALT and/or AST \>3× upper limit of normal) or renal impairment (creatinine clearance \<30 mL/min). 4. Severe cardiovascular or cerebrovascular disease. 5. Alcohol abuse or substance abuse. 6. Known pregnancy or lactation, or a positive pregnancy test prior to randomization. 7. Contraindication or hypersensitivity to any medications used in the study. 8. Initiation or dose adjustment of any preventive migraine therapy within 3 months prior to study drug administration. 9. Use of any other anti-vertigo or analgesic medication within 6 hours before study drug administration. 10. Participation in another interventional clinical study that could affect outcome assessment. 11. Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study or poses significant risk.

Study locations

1 study location is listed.

Recruiting site status is explicitly provided for 1 location; 1 is listed as Recruiting.

Countries: China

  • Hubei, China: 1

Sample of listed locations

  • Tongji Hospital — Wuhan, Hubei, 430040, China — Recruiting

Study details

Start date
December 1, 2025
Primary completion date
November 30, 2027
Completion date
December 1, 2027
First posted
October 13, 2026
Collaborators
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan No.1 Hospital, Wuhan Puren Hospital, Xiangyang Central Hospital, Xinyang Central Hospital

Source and update information

Source
ClinicalTrials.gov
NCT ID
NCT07871097
Registry last updated
October 13, 2026
QualifiedStudies registry data refreshed
October 19, 2026
QualifiedStudies record fetched
October 19, 2026

View NCT07871097 on ClinicalTrials.gov

Trial information can change. Confirm current study details with the study team or the registry.

About joining clinical research

Find clinical trials you may match with

QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.

Find clinical trials you may match with | Migraines studies | Clinical trial FAQ